Orchid Pharma and Cipla Team To Unveil New Drug in India

Orchid Pharma Limited, a Chennai-based Indian pharmaceutical firm, has declared the availability of a new drug, cefepime-enmetazobactam, which has been endorsed for the treatment of complex urinary tract infections (cUTI), hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia. In a historic collaboration, Orchid Pharma has teamed with Cipla Limited (Cipla) to enable the widespread and speedy distribution of this breakthrough antibiotic combination throughout India.

The introduction of cefepime-enmetazobactam represents a huge step forward for India's pharmaceutical industry in the fight against AMR, a growing worldwide health concern, and reinforces India's leadership in medical innovation. Orchid Pharma and Cipla believe that this collaboration will establish a new standard for addressing key healthcare concerns through strategic collaborations and sophisticated research. The collaboration between Orchid Pharma and Cipla brings together Orchid's novel medicine development skills with Cipla's substantial distribution network and market presence. This alliance intends to get this life-saving drug to healthcare providers across India as fast and efficiently as feasible.

Speaking on the launch, Manish Dhanuka, managing director Orchid Pharma said, "With increasing resistance to the current drugs most commonly used for treatment of these indications – e.g. piperacillin-tazobactam for cUTI – doctors were forced to start using carbapenems – a reserve drug meant to be used when most other drugs don't work. Now, Orchid's cefepime-enmetazobactam will allow doctors to spare carbapenems, prolonging their effective life by restricting their use."